Today: 29 January 2026
Subscribe
Browse Category

Biotech Stocks News 29 September 2025 - 20 October 2025

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain Investing. The prior day, RANI had closed at just $0.47,…
20 October 2025
····
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In

What to Know Before Markets Open on October 20, 2025 FDA Breakthrough News Ignites Rally Spruce Biosciences’ meteoric rise began with a game-changing regulatory win. On October 6, the company announced that the FDA had granted Breakthrough Therapy Designation (BTD) to its lead drug, tralesinidase alfa (TA-ERT) ts2.tech. TA-ERT is an experimental enzyme replacement therapy targeting Sanfilippo Syndrome Type B…
19 October 2025
···
Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets to speed drug discovery ts2.tech. In early October 2025 the stock showed wild swings: it plunged to the mid-$5s then rebounded ~16% on Oct 8 after an AI-focused tech conference and pipeline news ts2.tech ts2.tech. As of mid-day Oct 16,…
16 October 2025
···
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20 Sec. In VIRAGE, the oncolytic adenovirus…
15 October 2025
····
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist Reuters. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeutics Reuters. This potential acquisition would build on the companies’ ongoing partnership: J&J’s…
10 October 2025
····
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells Adaptimmune.…
9 October 2025
···
1 … 4 5 6

Stock Market Today

  • Foresight Group Holdings conducts share buyback purchasing 39,726 shares
    January 29, 2026, 2:16 AM EST. Foresight Group Holdings Limited announced a purchase of 39,726 ordinary shares on January 28, 2026, as part of its ongoing share buyback programme initiated in April 2025. The shares were acquired at prices ranging from 427 to 433 GBp, with a volume-weighted average price of 431.6 GBp. Post-transaction, the Group holds a total of 1,508,272 shares in treasury, which carry no voting rights. Overall, 3,159,956 ordinary shares have been repurchased under the programme. The buyback was executed through Berenberg on the London Stock Exchange. The total Ordinary Shares in issue stand at 116,347,803, with 114,839,531 carrying voting rights. This latest activity reflects Foresight's strategy to optimize its capital structure.
Go toTop